Abstract
TRK-530 is a novel synthetic bisphosphonate compound which exhibits inhibitory activity in the rat adjuvant arthritis (AA) model. We found that, during AA development, the concentrations of cytokine-induced neutrophil chemoattractant-1 (CINC-1) and tumor necrosis factor alpha (TNF-alpha) in the bone marrow increased, and that administration of TRK-530 decreased the concentrations of these cytokines. The suppression of these concentration increases paralleled the inhibition of paw edema. Paw edema inhibition by TRK-530 in rat AA may be the result of decreasing CINC-1 and TNF-alpha concentrations.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
-
Arthritis, Experimental / metabolism*
-
Bone Marrow / drug effects
-
Bone Marrow / metabolism*
-
Chemokine CXCL1
-
Chemokines, CXC / metabolism
-
Chemotactic Factors / metabolism
-
Cytokines / metabolism*
-
Diphosphonates / pharmacology*
-
Female
-
Foot / pathology
-
Growth Substances / metabolism
-
Inflammation / metabolism*
-
Intercellular Signaling Peptides and Proteins*
-
Rats
-
Rats, Inbred Lew
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Chemokine CXCL1
-
Chemokines, CXC
-
Chemotactic Factors
-
Cxcl1 protein, rat
-
Cytokines
-
Diphosphonates
-
Growth Substances
-
Intercellular Signaling Peptides and Proteins
-
TRK 530
-
Tumor Necrosis Factor-alpha